Health Care • Biotechnology: Pharmaceutical Preparations
$106.20 ▲ +1.63
(+1.56%)
MKT CAP: $180.95B • VOL: 8.44M
52W L $82 52W H $132
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$89
MEDIAN
$119
MEAN
$121
HIGH
$144
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABT TAPE
ABT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $128.50 | $122.13 | 2025-02-14 | $96.64 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $133.81 | $125.32 | 2025-02-06 | $99.83 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $121.07 | $116.82 | 2025-01-29 | $101.95 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $108.32 | — | 2025-01-17 | $104.08 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $93.46 | $100.89 | 2025-01-09 | $94.52 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $126.38 | $110.45 | 2024-12-18 | $92.39 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $103.01 | $107.26 | 2024-12-04 | $98.77 | -4.3% | 48% | C |